Stocks struggled at the beginning of the week - Monday Review, November 30

Stocks struggled at the beginning of the week - Monday Review, November 30

Vaccine news is starting to lose its effect on the markets. New Sino-US tensions are in focus

The US

The majority of benchmarks ended in the red as the Trump Administration was considering banning two major Chinese entities: SMIC and CNOOC. USA30 fell 1.1%, while USA500 went down 0.5%. TECH100 rose 0.04%.

Crude Oil lost 0.4% and traded at $45.34 per barrel.

Gold traded at $1,780.86 per ounce after it closed down 0.4%.

The Dollar Index traded at 91.847 after it gained 0.05%.

Asia and Australia

Japan225 gained 0.01% after the industrial production grew 3.8% in October, missing the 3.9% consensus.

HongKong45 edged down 0.18% as the number of COVID-19 infections continued to rise, leading to schools’ closure.

Down under, Australia200 lost 0.71% ahead of the Reserve Bank’s monetary policy meeting.

Europe

Even though Pfizer’s vaccine could receive approval from the UK’s regulators didn’t move the markets. Moreover, the fact that the European Medicines Agency could consider both Pfizer’s and Moderna’s vaccines eligible for use, left the benchmarks unimpressed. Europe50 slipped 1%, while Germany30 was down 0.3%.

France40 fell 1.4%. UK100 inched 1.6% lower.

Brent Oil traded 0.6% lower at $48.18 a barrel.

EUR/USD closed 0.07% lower at 1.1954.

Sources: marketwatch.com, investing.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com

JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.